Impact of Treatment and Imaging Modalities on 5-Year Net Survival of 11 Cancers in 200 Countries
2020
This analysis describes the development of a microsimulation model of stage-specific cancer survival in 200 countries/territories for 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). The paper estimated current 5-year net survival for diagnosed cancers in each country and potential survival gains from increasing the availability of individual treatment and imaging modalities, and more comprehensive packages of scale-up. Global 5-year net survival for all 11 cancers (combined) is estimated to be 42.6% (95% UI 40.3-44.3), with survival in high-income countries an average of 12 times (range 4-17) higher than in low-income countries. Simultaneous expansion of treatment, imaging, and quality of care could improve 5-year net survival by more than ten times in low-income countries (3.8% [95% UI 0.5-9.2] to 45.2% [40.2-52.1]) and could more than double 5-year net survival in lower-middle-income countries (20.1% [7.2-31.7] to 47.1% [42.8-50.8]). Scaling up both treatment and imaging availability could yield synergistic survival gains for patients with cancer, and expanding traditional modalities in lower-income settings might be a feasible pathway to improve survival before scaling up more modern technologies.
Impact of Treatment and Imaging Modalities on 5-Year Net Survival of 11 Cancers in 200 Countries
Source:
Ward ZJ, Scott AM, Hricak H et al. Estimating the Impact of Treatment and Imaging Modalities on 5-Year Net Survival of 11 Cancers in 200 Countries: A Simulation-Based Analysis. The Lancet Oncology 2020; 21 (8): 1077-1088. https://doi.org/10.1016/s1470-2045(20)30317-x
Not open access.